company background image
UTHR logo

United Therapeutics NasdaqGS:UTHR Stock Report

Last Price

US$229.72

Market Cap

US$11.4b

7D

-3.0%

1Y

4.9%

Updated

28 Mar, 2024

Data

Company Financials +

United Therapeutics Corporation

NasdaqGS:UTHR Stock Report

Market Cap: US$11.4b

UTHR Stock Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

UTHR fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance5/6
Financial Health5/6
Dividends0/6

United Therapeutics Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for United Therapeutics
Historical stock prices
Current Share PriceUS$229.72
52 Week HighUS$261.54
52 Week LowUS$204.44
Beta0.52
1 Month Change1.31%
3 Month Change4.47%
1 Year Change4.90%
3 Year Change19.43%
5 Year Change93.87%
Change since IPO3,669.76%

Recent News & Updates

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Mar 20

Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Mar 15
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Recent updates

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Mar 20

Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Mar 15
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Jan 02
Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Dec 08
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Nov 16
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Sep 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Aug 07
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

May 22
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

Apr 25
Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

Feb 06
We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jan 16
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 20
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

United Therapeutics: Ability To Expand Tyvaso To Large IPF Market

Aug 24

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Aug 04
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

United Therapeutics Q2 2022 Earnings Preview

Aug 02

These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely

Jul 17
These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely

United Therapeutics reaches all-time high; shares up 15% YTD

Jul 06

Why Hold United Therapeutics After Shares Doubled?

Jun 08

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Is Interesting

May 06
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Is Interesting

We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

Apr 16
We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

Shareholder Returns

UTHRUS BiotechsUS Market
7D-3.0%0.9%0.2%
1Y4.9%11.0%28.1%

Return vs Industry: UTHR underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: UTHR underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is UTHR's price volatile compared to industry and market?
UTHR volatility
UTHR Average Weekly Movement3.6%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: UTHR has not had significant price volatility in the past 3 months.

Volatility Over Time: UTHR's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19961,168Martine Rothblatthttps://www.unither.com

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.

United Therapeutics Corporation Fundamentals Summary

How do United Therapeutics's earnings and revenue compare to its market cap?
UTHR fundamental statistics
Market capUS$11.45b
Earnings (TTM)US$984.80m
Revenue (TTM)US$2.33b

11.0x

P/E Ratio

4.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UTHR income statement (TTM)
RevenueUS$2.33b
Cost of RevenueUS$257.50m
Gross ProfitUS$2.07b
Other ExpensesUS$1.09b
EarningsUS$984.80m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)20.93
Gross Margin88.94%
Net Profit Margin42.31%
Debt/Equity Ratio11.7%

How did UTHR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.